J&J scratches AD itch by acquiring experimental eczema antib

J&J scratches AD itch by acquiring experimental eczema antibody for $1.25B

J&J will pick up Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab Therapeutics, for $1.25 billion to acquire all assets related to NM26.

Related Keywords

Jersey , David Urech , David Lee , Ambrx Biopharma , Johnson , Drug Administration , Johnson Innovative Medicine , Yellow Jersey Therapeutics , Numab Therapeutics ,

© 2025 Vimarsana